Pieris Pharmaceuticals (PIRS)
(Delayed Data from NSDQ)
$16.75 USD
+0.34 (2.07%)
Updated Aug 14, 2024 04:00 PM ET
After-Market: $16.77 +0.02 (0.12%) 6:44 PM ET
NA Value
NA Growth NA Momentum NA VGMBrokerage Reports
Pieris Pharmaceuticals, Inc. [PIRS]
Reports for Purchase
Showing records 1 - 20 ( 91 total )
Company: Pieris Pharmaceuticals, Inc.
Industry: Medical - Biomedical and Genetics
Company: Pieris Pharmaceuticals, Inc.
Industry: Medical - Biomedical and Genetics
3Q21 Results; Pipeline Forges Ahead; Key Inflection Points Anticipated in Upcoming Year
Provider: H.C. Wainwright & Co., Inc.
Analyst: PANTGINIS J
Company: Pieris Pharmaceuticals, Inc.
Industry: Medical - Biomedical and Genetics
Company: Pieris Pharmaceuticals, Inc.
Industry: Medical - Biomedical and Genetics
Preclinical Data Are an Intriguing Hint at What''s in Store for PRS-220''s Clinical Development
Provider: H.C. Wainwright & Co., Inc.
Analyst: PANTGINIS J
Company: Pieris Pharmaceuticals, Inc.
Industry: Medical - Biomedical and Genetics
2Q21 Results; Strategic Partnerships and Strong Financials Solidify Rich Pipeline Development
Provider: H.C. Wainwright & Co., Inc.
Analyst: PANTGINIS J
Company: Pieris Pharmaceuticals, Inc.
Industry: Medical - Biomedical and Genetics
Introducing PRS-220; New Initiative in IPF Gets a Cash Jump Start
Provider: H.C. Wainwright & Co., Inc.
Analyst: PANTGINIS J
Company: Pieris Pharmaceuticals, Inc.
Industry: Medical - Biomedical and Genetics
New Partnership, New Assets Coming; Pieris Continues to Deliver on Platform
Provider: H.C. Wainwright & Co., Inc.
Analyst: PANTGINIS J
Company: Pieris Pharmaceuticals, Inc.
Industry: Medical - Biomedical and Genetics
1Q21 Results; Many Hands Make Light Work, Multiple Partnerships Boost Clinical Pipeline
Provider: H.C. Wainwright & Co., Inc.
Analyst: PANTGINIS J
Company: Pieris Pharmaceuticals, Inc.
Industry: Medical - Biomedical and Genetics
Company: Pieris Pharmaceuticals, Inc.
Industry: Medical - Biomedical and Genetics
Oncology Assets'' Profiles Continue to Strengthen
Provider: H.C. Wainwright & Co., Inc.
Analyst: PANTGINIS J
Company: Pieris Pharmaceuticals, Inc.
Industry: Medical - Biomedical and Genetics
2020 Results; PRS-060 Enters Phase 2a Trial; Important Updates at AACR
Provider: H.C. Wainwright & Co., Inc.
Analyst: PANTGINIS J
Company: Pieris Pharmaceuticals, Inc.
Industry: Medical - Biomedical and Genetics
PRS-343 Reach Broadens; New Trial and Strategic Cash Received
Provider: H.C. Wainwright & Co., Inc.
Analyst: PANTGINIS J
Company: Pieris Pharmaceuticals, Inc.
Industry: Medical - Biomedical and Genetics
Path Cleared for PRS-343; Looking Forward to Phase 2 Gastric Study
Provider: H.C. Wainwright & Co., Inc.
Analyst: PANTGINIS J
Company: Pieris Pharmaceuticals, Inc.
Industry: Medical - Biomedical and Genetics
3Q20 Results; Checking Important Boxes to Push Programs Forward
Provider: H.C. Wainwright & Co., Inc.
Analyst: PANTGINIS J
Company: Pieris Pharmaceuticals, Inc.
Industry: Medical - Biomedical and Genetics
PRS-343 Continues Its Positive Push Forward
Provider: H.C. Wainwright & Co., Inc.
Analyst: PANTGINIS J
Company: Pieris Pharmaceuticals, Inc.
Industry: Medical - Biomedical and Genetics
2Q20 Results; Momentum Continues to Build Across Programs
Provider: H.C. Wainwright & Co., Inc.
Analyst: PANTGINIS J
Company: Pieris Pharmaceuticals, Inc.
Industry: Medical - Biomedical and Genetics
PRS-343 Delivery to Be Tweaked; See Minor Impact to Timelines
Provider: H.C. Wainwright & Co., Inc.
Analyst: PANTGINIS J
Company: Pieris Pharmaceuticals, Inc.
Industry: Medical - Biomedical and Genetics
1Q20 Results; PRS-343 and PRS-060 Ready for Next Steps
Provider: H.C. Wainwright & Co., Inc.
Analyst: PANTGINIS J
Company: Pieris Pharmaceuticals, Inc.
Industry: Medical - Biomedical and Genetics
Focus and Decisions out of Servier Partnership
Provider: H.C. Wainwright & Co., Inc.
Analyst: PANTGINIS J
Company: Pieris Pharmaceuticals, Inc.
Industry: Medical - Biomedical and Genetics
2019 Results; Important Boost in Visibility Expected in 2020 for PRS-060 and PRS-343
Provider: H.C. Wainwright & Co., Inc.
Analyst: PANTGINIS J